

LICENSING OPPORTUNITY: ANTIBODIES TARGETING MARBURGVIRUS GLYCOPROTEINS AND USES THEREOF

DESCRIPTION

Problem

There are no vaccines or antiviral treatments approved for Marburgvirus disease. No monoclonal antibodies against Marburgviruses are currently approved for clinical use by the FDA.

Invention

Our study describes the discovery and characterization of a diverse panel of antibodies against marburgvirus GP (glycoprotein) induced by multivalent immunization and provides candidate immunotherapeutics for further study and development.

BENEFITS

Potential Commercial Applications

Prophylactic or therapeutic countermeasures to marburgvirus infection outbreaks.

Competitive Advantage

Potential for protective immunity to Marburgvirus.

Contact: licensing@nist.gov

NIST TECHNOLOGY PARTNERSHIPS
OFFICE

NIST Technology Partnerships Office
National Institute of Standards and Technology
100 Bureau Drive, Gaithersburg, MD 20899-2200